Tim has 40 years’ international senior level business experience in the Healthcare, Biotech and Technology sectors.
He is also CEO of ImmuPharma PLC an AIM quoted specialist drug discovery and development company and Chairman of 4basebio PLC, an AIM quoted company developing next generation gene therapy technologies and solutions.
Tim is a former CEO and Finance Director of a number of public and private companies, including Alizyme plc and Peptide Therapeutics Group plc. He has also co-founded a number of healthcare and biotechnology companies. A Fellow of the Association of Chartered Certified Accountants, he also has an MBA from Cranfield School of Management.
Dr Simon Ward
Chief Executive Officer
Simon is a co-founder of Incanthera and has more than 30 years’ senior experience in academia and business.
He was a founder and CEO of Molecular SkinCare Limited, a pioneer and developer of novel dermatology products for the prevention and management of skin diseases. As CSO of York Pharma plc, he was responsible for bringing innovative dermatology product through to market. Simon also served as chairman of South Yorkshire Bioscience Enterprise Network (SYBEN) and deputy chairman of Medipex, a healthcare innovation hub for NHS organisations across industry and academia internationally.
Simon graduated from the University of London’s School of Pharmacy (UK) with a Joint Honours Degree in Pharmacology and Toxicology and was awarded a DPhil in the Department of Human Anatomy, Oxford University under a Glaxo Group Research Studentship.
Dr Alan Warrander
Independent Non-Executive Director
Remuneration Committee Chair
Alan is an expert in partnering and licensing with significant experience of global pharma drug discovery and drug development processes having more than 30 years’ experience in the Pharmaceutical Industry, including 21 years with AstraZeneca, holding many positions including Director of Global Licensing.
He has a BSc in Chemistry and Biochemistry and a PhD in Biochemistry.